apremilast,deucravacitinib
amgen,bms
['psoriasis', 'deucrava', 'deucra', 'otezla', '$bmy']
fda approval for $bmy sotyktu deucravacitinib sets the first-in-class #tyk2 inhibitor up to supplant #otezla as the oral therapy of choice for psoriasis 
The leading voice for decision-makers throughout the global biopharma ecosystem. 
Free weekly podcast "BioCentury This Week": https://t.co/6CfHh0mIT6